U.S. Marine and Shipping Stock News

What Ionis’ latest update means for shareholders Ionis Pharmaceuticals (IONS) kicked off 2026 by spotlighting 2025 milestones, including US$105 million in preliminary TRYNGOLZA net sales and progress across several late stage RNA therapies with key regulatory and clinical updates ahead. For you as a shareholder or potential investor, this kind of multi program update matters because it links current commercial performance with a set of upcoming decision points that could influence Ionis'...

Morgan Stanley’s downgrade of American Assets Trust (AAT) to Underweight, tied to weak growth concerns, large lease expirations, and a possible 2027 dividend reduction, has quickly become the focal point for investors. See our latest analysis for American Assets Trust. At a share price of $18.06, American Assets Trust has experienced pressure over time, with a 90 day share price return of 10.19% and a 1 year total shareholder return of 23.04%, pointing to fading momentum as recent news,...

Upcoming earnings put JetBlue back in the spotlight JetBlue Airways (JBLU) is back on investors’ radar as it heads into its fourth quarter 2025 earnings report on January 27, 2026, with expectations calling for a wider loss despite modest revenue growth. See our latest analysis for JetBlue Airways. At a share price of $5.16, JetBlue has had a mixed year, with an 11.69% 3 month share price return and a 7.50% 1 month share price return sitting against a 35.18% 1 year total shareholder return...

Gold Resource Corporation reported a past fourth‑quarter 2025 operational turnaround at its Don David Gold Mine, with higher‑grade ore from the Three Sisters area driving record silver sales and a shift toward silver‑weighted production. This operational improvement marks a meaningful change in the company’s revenue mix, increasing its exposure to silver‑linked performance at the Don David operation. We’ll now look at how this operational turnaround and Three Sisters’ higher‑grade ore shape...

First American Financial (FAF) is back in focus after its title insurance subsidiary rolled out a free property title monitoring and fraud alert service for eligible customers, directly targeting rising concerns around real estate fraud. See our latest analysis for First American Financial. The share price is at US$61.30, and recent moves have been mixed, with a 3.23% 7 day share price return set against a 2.68% 30 day share price decline. The 1 year total shareholder return of 1.56% and 5...

Hasbro, Inc. recently appointed Doug Bowser, former President and Chief Operating Officer of Nintendo of America, and Carla Vernón, Chief Executive Officer of The Honest Company, to its Board of Directors, while also scheduling the release of its fourth-quarter and full-year 2025 results for February 10, 2026. The combination of gaming leadership experience and consumer-brand transformation expertise on the new Board, alongside heightened expectations for upcoming earnings, is drawing...

Why AXT stock is back in focus after a rating change AXT (AXTI) is back on investors’ radar after Needham analyst Charles Shi cut the stock to a hold rating, a shift that appears to be influencing sentiment and recent price swings. See our latest analysis for AXT. While the downgrade and recent volatility, including the share price pullback earlier in January, have cooled near term sentiment, AXT’s recent momentum is still striking. It has a 30 day share price return of 46.14%, a 90 day share...

Earlier in January, Molson Coors Beverage reported adjusted earnings that exceeded Wall Street expectations but reduced its full-year earnings outlook, citing economic pressures and aluminum tariffs. This mix of better-than-expected quarterly results and a more cautious earnings outlook has prompted analysts and investors to reassess the company’s prospects. Next, we’ll examine how this lowered full-year earnings outlook influences Molson Coors’ investment narrative and what it may mean for...

Why Structure Therapeutics (GPCR) Is Back on Investors’ Radar Structure Therapeutics (GPCR) is drawing fresh attention after recent analyst commentary pointed to growing confidence in its obesity pipeline, including key trial progress for aleniglipron and a new licensing deal with Genentech. The agreement with Genentech includes a US$100 million upfront payment and potential royalties, while analysts are watching upcoming clinical milestones such as the 44 week ACCESS II readout and a planned...

In recent days, CoreCivic has attracted heightened investor interest following speculation that it may secure a new government contract with the Naval Supply Systems Command. This potential agreement is drawing attention because it could reinforce CoreCivic’s role as a key private provider of services to U.S. government agencies, even amid mixed financial signals and risk considerations. Next, we’ll examine how speculation around the Naval Supply Systems Command contract shapes CoreCivic’s...

Why China Yuchai International (CYD) is on investors’ radar China Yuchai International (CYD) has caught attention after a strong share price move over the past month, prompting investors to reassess how its engine manufacturing and hospitality businesses line up with current expectations. See our latest analysis for China Yuchai International. At a share price of $43.94, China Yuchai International has had a strong run, with a 30 day share price return of 21.15% and a very large 1 year total...

LKQ Corporation recently reported a Q3 2025 earnings beat and raised its 2025 adjusted EPS guidance to a range of US$3 to US$3.15, even as analysts now expect a year-on-year earnings decline for Q4 2025. This combination of stronger-than-expected recent performance and higher full-year guidance, set against forecasts for softer Q4 results, has sharpened investor focus on the company’s earnings quality and outlook. We’ll now look at how LKQ’s raised 2025 adjusted EPS guidance shapes its...

MBX Biosciences (MBX) is back on investor watchlists after Guggenheim issued a series of supportive research updates, highlighting the company’s obesity drug pipeline and upcoming clinical milestones as key factors to monitor. See our latest analysis for MBX Biosciences. The latest Guggenheim commentary arrives after a sharp move in MBX Biosciences’ shares, with a 1 day share price return of 6.44% and a 90 day share price return of 191.88%. The 1 year total shareholder return of 321.70%...

What the ANA partnership means for OUTFRONT Media OUTFRONT Media (OUT) has joined the Association of National Advertisers as a 2026 Strategic Partner, becoming the first out of home media company in the program and securing a seat at key brand marketing forums. For you as an investor, this is less about a single contract and more about access. The company is positioning itself directly in front of senior marketers who control large advertising budgets, while showcasing its in real life media...

Recent performance snapshot for W. P. Carey (WPC) With no single headline event driving attention, W. P. Carey (WPC) is drawing interest as investors weigh its recent share performance, income profile, and valuation signals across the past year. See our latest analysis for W. P. Carey. At a share price of $69.93, W. P. Carey has seen a 30 day share price return of 8.22%, while its 1 year total shareholder return of 30.09% points to momentum that has been building rather than fading. If you...

What recent performance says about TransMedics Group (TMDX) With no single headline event driving attention today, TransMedics Group (TMDX) has still attracted interest after a mixed short term stretch and strong longer term returns that stand out among healthcare names. The stock is roughly flat over the past week after a 1% decline in the last session, yet it has returned about 11% over the past month and around 19% in the past 3 months. Longer horizons look very different, with year to...

What recent price moves suggest about FuboTV (FUBO) FuboTV (FUBO) has seen mixed share performance recently, with a 3.7% decline over the past day and a 3% fall over the past month, while year-to-date returns are slightly negative. See our latest analysis for FuboTV. With the share price at US$2.57 and a modestly negative year to date share price return, recent weakness suggests momentum has cooled slightly as investors reassess FuboTV’s growth prospects and risk profile in live TV...

DENTSPLY SIRONA recently renewed its long-standing U.S. dental technology distribution agreement with Patterson Dental and expanded its collaboration with Benco Dental to include a broad suite of connected digital solutions, while also adding former Patterson CEO Donald J. Zurbay to its Board and creating a Growth and Value Creation Committee. Together, these moves deepen Dentsply Sirona’s distribution reach and bring insider dealer expertise directly into board-level oversight as the...

If you are wondering whether Power Integrations is attractively priced or still has work to do before looking compelling, its recent price moves and valuation checks give you some useful clues. The share price last closed at US$42.90, with returns of 4.9% over the past week and 17.3% over the past month. The year to date return is 15.0% and the 1-year return is a 30.9% decline. Recent coverage has focused on how Power Integrations fits into the wider semiconductor space and how investors are...

If you are wondering whether Zoetis is starting to look interesting at today’s price, you are not alone, and a closer look at its valuation might help you decide how it fits into your watchlist. The stock last closed at US$123.24 and has seen a 1.1% decline over the past week, a 0.8% gain over the past month, and a 2.1% decline year to date, while the 1 year and 3 year returns of 25.4% and 23.1% declines show how sentiment has shifted over time. Recent coverage has focused on Zoetis as a key...

Johnson Controls International (NYSE:JCI) disclosed CEO Joakim Weidemanis's 2025 compensation package in a recent SEC filing. The filing also highlighted insider activity, with several executives selling JCI shares and no corresponding insider purchases reported. Investors are watching these disclosures closely as they assess leadership incentives and insider sentiment toward the company. Johnson Controls International, known for building solutions, HVAC systems and industrial controls,...

Why Owens Corning (OC) is on investors’ radar today Owens Corning (OC) has drawn fresh attention after recent trading left the shares with mixed short term performance, including a 1 day decline and a small 7 day pullback, alongside generally positive longer term returns. See our latest analysis for Owens Corning. At a share price of US$120.89, Owens Corning has seen short term share price pressure with a 1 day decline but a positive year to date share price return of 5.9%. The 1 year total...

If you are wondering whether Array Digital Infrastructure is still fairly priced after its recent run, this article walks through what the current share price could imply about the company's value. The stock last closed at US$56.55, with returns of 5.4% over 7 days, 9.0% over 30 days, 4.7% year to date and 28.5% over 1 year, plus a very large 3 year gain and a 136.8% return over 5 years. Recent news coverage has focused on Array Digital Infrastructure's position in digital infrastructure and...

Event context and recent return profile Saia (SAIA) has moved quietly on the back of recent trading rather than a single headline event. This puts the focus on how its share performance lines up with the underlying business. Over the past month the stock shows a 6.4% gain, while the past 3 months and 1 year reflect moves of about 10.2% and a 32.6% decline, respectively. This sets a mixed backdrop for investors to evaluate. See our latest analysis for Saia. The recent 1 day and 7 day share...